Loading organizations...
Ardelyx has raised $30.0M across 1 funding round.
Key people at Ardelyx.
Ardelyx has raised $30.0M in total across 1 funding round.
Ardelyx is a commercial biopharmaceutical company based in Waltham, Massachusetts, that discovers, develops, and commercializes targeted therapeutics for gastrointestinal and cardiorenal diseases. The publicly traded enterprise focuses on minimally systemic medicines that act locally in the gastrointestinal tract, generating revenue through direct commercial sales of its approved prescription drugs IBSRELA and XPHOZAH. Operating with a workforce of approximately 350 employees, the biotechnology firm has reached a market capitalization of nearly two billion dollars and secured over 61 million dollars in total venture funding. The organization has received institutional backing from notable investors including New Enterprise Associates and Amgen Business Development, while establishing strategic international licensing partnerships with pharmaceutical entities like Kyowa Kirin and Fosun Pharma. The business was originally founded in 2007 by Peter Schultz, Dominique Charmot, and Jean Frechet to address unmet medical needs through novel therapies.
Ardelyx has raised $30.0M across 1 funding round. Most recently, it raised $30.0M Series B in August 2011.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2011 | $30M Series B | — | EQT Life Sciences, Mott Family Capital, Amgen Ventures, CMEA Capital, NEA | Announced |
Key people at Ardelyx.
Ardelyx has raised $30.0M in total across 1 funding round.
Ardelyx's investors include EQT Life Sciences, Mott Family Capital, Amgen Ventures, CMEA Capital, NEA.
Ardelyx is a publicly traded biopharmaceutical company, not a technology company, focused on discovering, developing, and commercializing first-in-class medicines for unmet medical needs in gastrointestinal and kidney disease areas.[1][2][3] Its approved products include IBSRELA® (tenapanor) for irritable bowel syndrome with constipation (IBS-C) and XPHOZAH® (tenapanor) for controlling serum phosphorus in chronic kidney disease (CKD) patients on dialysis.[1][3][5] Ardelyx serves patients with serious conditions like hyperphosphatemia and IBS-C, addressing problems such as elevated phosphate levels and chronic constipation through novel mechanisms like NHE3 inhibition, with growth shown via recent real-world evidence studies and international partnerships.[1][3]
The company emphasizes patient-focused innovation, supported by programs like ArdelyxAssist for access and affordability, and maintains a pipeline including a Phase 2 program for hyperkalemia (RDX013) and early-stage efforts in metabolic acidosis and RDX10531.[1][4][5]
Founded in 2007 and headquartered in Waltham, Massachusetts, Ardelyx emerged from a discovery model where scientists identified new biological mechanisms to target unmet needs in patient care.[1][2] Early focus centered on innovative medicines for gastrointestinal disorders, leading to the development of tenapanor, its flagship molecule, which gained FDA approval for IBSRELA and later XPHOZAH after successful Phase 3 trials.[1][5] Pivotal moments include establishing partnerships with Kyowa Kirin (Japan), Fosun Pharma (China), and Knight Therapeutics (Canada) for tenapanor commercialization, alongside navigating regulatory approvals amid complex biopharma challenges.[1][6]
Ardelyx rides the wave of precision biopharma innovation in nephrology and gastroenterology, where rising CKD prevalence—driven by aging populations and diabetes—creates demand for targeted therapies beyond traditional binders.[3] Timing aligns with post-pandemic focus on outpatient kidney care and real-world evidence, as seen in 2025 ASN Kidney Week data on XPHOZAH's efficacy.[3] Market forces like unmet needs in hyperphosphatemia (affecting most dialysis patients) and IBS-C's quality-of-life impact favor its novel, non-systemic approaches, influencing the ecosystem through partnerships that accelerate global adoption and set standards in patient engagement.[1][3]
Ardelyx's momentum positions it for expansion via pipeline advancements like RDX013 in hyperkalemia and RDX10531's multi-area potential, alongside growing XPHOZAH uptake supported by real-world data.[3][5] Trends in CKD management, international markets, and digital patient services will shape its path, potentially amplifying influence through further approvals and ecosystem collaborations. As a biopharma leader delivering medicines that matter, Ardelyx continues transforming care for underserved patients, correcting the misconception of it as a pure tech firm by exemplifying biotech's innovative core.[2][3]
